World leading cancer diagnostics expert, Professor Aldo Scarpa appointed to Immunovia’s Scientific Advisory Board
LUND, Sweden ― In line with Immunovia´s strategy to deliver the first validated test for early diagnosis of pancreatic cancer, the company announced today that Professor Aldo Scarpa has been appointed to the company’s Scientific Advisory Board. Professor Scarpa is the Director of the ARC-Net Research Centre for Applied Research on Cancer and Chair of the Department of Pathology and Diagnostics at the University and Hospital Trust of Verona in Italy.
Prof. Scarpa received his MD from the University of Padua and his PhD in Human Oncology and Molecular Pathology from the University of Verona. He trained in Japan at the National Cancer Center of Tokyo, at the New York University and La Jolla Cancer Research Center, USA, and at the Nürnberg Universität, Germany.
He leads the Cancer Biobank Network Programme in the Veneto Region (Italy) (population 4,900,000), and is Chief of the Diagnostic Molecular Pathology Laboratory, officially recognised by the Veneto Government as one of two referral centers for cancer molecular diagnostics in the region and leader of the Italian effort in the International Cancer Genome Consortium funded by the Italian Ministry of Research and Ministry of Health. He is also a Principle Investigator of the Italian National Consortium for early diagnostics in cancer funded by the Italian Association for Cancer research (AIRC.
“We are delighted that Professor Scarpa has joined Immunovia’s Scientific Advisory Board. As a world leading expert on the translation into clinical practice of molecular diagnostics of cancers with clinical relevance, he brings invaluable experience and insights to our pancreatic cancer program,” said Mats Grahn, CEO, Immunovia.
Professor Scarpa adds: “An early diagnostic for pancreatic cancer is essential if we are to take full advantage of advances in surgical techniques and increase survival rates for this devastating disease. I therefore look forward to contributing to the successful development of Immunovia’s IMMray™ PanCan-d.”
For more information, please contact:
Mats Grahn
Chief Executive Officer, CEO, Immunovia
Tel.: +46-70-5320230
Email: mats.grahn@immunovia.com
About Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com)
Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com.
About Pancreatic Cancer
Pancreatic Cancer is one of the most deadly and difficult to detect cancers, as the signs and symptoms are diffuse and similar to other diseases. There are more than 40,000 deaths and over 50,000 new cases diagnosed each year in the U.S. alone, and the five-year survival rate for pancreatic cancer is currently 4-6%. It is predicted to become the second leading cause of cancer death by 2020. However, because resection is more successful in stage I/II, can significantly improve pancreatic cancer patients’ 5-year survival rates from 4-6% to potentially 50-60%.
###
Tags: